KRAS and lung cancer: Here, we evaluated the immunomodulatory effects of F+D in vitro and in vivo using the novel syngeneic KRAS+ murine lung cancer model, FVBW-17, derived from a lung adenocarcinoma induced by exposure of an FVB/N mouse to the tobacco carcinogen NNK [11].